VivoSeq
Nephrology

Hepatorenal Syndrome

21

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Hepatorenal Syndrome is an emerging landscape with 21 programs across 8 companies. The most active players are Cumberland Pharmaceuticals, Takeda, Laboratoire français de Fractionnement et de Biotechnologies. 1 therapy is approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

73/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cumberland Pharmaceuticals

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2L

Laboratoire français de Fractionnement et de Biotechnologies

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2L

La Jolla Pharmaceutical Company

2 programs

Phase 2Sun Pharma logo

Sun Pharma

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

23 of 26 classified programs — the dominant modality here.

12%ALL OTHERSPeptide312%

Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.

Analysis

Trial Status

27

clinical trials

Completed16 · 59%
Unknown status4 · 15%
Terminated3 · 11%
Withdrawn2 · 7%
Suspended1 · 4%
Recruiting1 · 4%

Clinical Trials

Trial Activity

27 trials

Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Recruiting·NNoorik Biopharmaceuticals AG·Phase 2·NCT06256432·54 enrolled
Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1
Completed·MMallinckrodt·Phase 3·NCT02770716·300 enrolled
Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease
Completed·UUniversity Hospital Freiburg·N/A·NCT06161766·490 enrolled
Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.
Completed·NNational Hepatology & Tropical Medicine Research Institute·Phase 4·NCT03455322·60 enrolled
Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome
Completed·LLahore General Hospital·N/A·NCT07460908·60 enrolled
Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT03822091·60 enrolled
Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis
Completed·HHospital Clinic of Barcelona·N/A·NCT01932151·18 enrolled
TYPE 2 HEPATORENAL SYNDROME
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT01637454·46 enrolled
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
Completed·CCumberland Pharmaceuticals·Phase 2·NCT01436500·55 enrolled
Noradrenalin vs Terlipressin in Hepatorenal Syndrome
Completed·UUniversity of Turin, Italy·Phase 3·NCT00370253·20 enrolled
Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients
Completed·SSamar Atef Sebaweh Mohammed·Phase 2·NCT05621005·104 enrolled
Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome
Completed·NNational Hepatology & Tropical Medicine Research Institute·N/A·NCT04522297·91 enrolled
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Completed·MMallinckrodt·Phase 3·NCT01143246·196 enrolled
A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
Completed·OOcelot Bio, Inc·Phase 2·NCT05309200·47 enrolled
Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg
Completed·UUniversity of Louisville·Phase 1·NCT02789150·18 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)